These services will help alleviate the impact of contraceptive deserts in the state.
stock.adobe.com
CVS Pharmacy announced that its locations in Massachusetts will start offering prescribing services for contraceptive medications.1 CVS pharmacists in the state will be able to provide evaluations and offer prescriptions for birth control. According to a press release from the company, this move is a response to data that shows that many women in the United States live in areas where they don’t have access to safe and effective birth control methods. Due to CVS’s nationwide presence, the addition of these services to its pharmacies will help provide better coverage in these areas.
In a press release, vice president of pharmacy health services for CVS Health Jinali Desai, PharmD, MBA, MPH, said, “Pharmacists are trusted and accessible health care providers who do much more than fill prescriptions. They have years of education and experience, and have the clinical ability to provide chronic, acute and preventive services for their patients. We're pleased to introduce this new service in Massachusetts to help increase access to birth control and further support women's unique health care needs."
CVS also issued a statement from Millbury Senator Michael Moore, who said, “Hormonal birth control is one of the safest and most effective ways to prevent unplanned pregnancy and support family planning, but many women find this critical medication difficult to obtain here in Massachusetts. Allowing local pharmacists to prescribe hormonal contraceptives when appropriate is something 27 states and D.C. already allow in some form – it's about time the Commonwealth joins them. I am so grateful to my colleagues in the Legislature for getting this provision signed into law, for our partners at pharmacies across Massachusetts, and the countless organizations and advocates that have tirelessly worked to bring awareness to this issue. We are taking a big step toward lowering barriers that prevent women from getting the birth control they need and addressing disparities in contraceptive access for those in historically underserved areas."
In the same press release, Somerville representative Christine Barber added, “Enabling pharmacists to prescribe hormonal birth control is an important step to address disparities in access to basic, necessary reproductive health care. I am proud that the legislature passed this important law to continue the Commonwealth's commitment to health equity and reproductive justice.”
Northampton representative Lindsay Sabadosa also said, “Patients deserve real access to reproductive health care, and the provision of birth control by pharmacists will allow patients to quickly consult with their pharmacists and get a birth control prescription that same day. With the addition of pharmacist-prescribed contraception in Massachusetts, we are putting choice back in the patients' hands and giving them options in how, where, and when they get their contraception.”
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.